after you join the study, you will sign an informed consent form that explains the purpose of the trial and what is expected of you.

the study staff will confirm that you meet the eligibility criteria for participants with relapsed or refractory multiple myeloma.

before any medication is given, you will undergo a series of tests that may include blood work, imaging, and evaluation of disease activity.

these assessments provide a reference point to compare later changes during the trial.

you will begin taking surzetoclax, which is provided as a film‑coated tablet taken by mouth.

the exact dose, how often you take the tablet, and the length of treatment will be defined by the study protocol and may be adjusted based on safety observations.

if you are assigned to the combination arm, you will also receive etentamig, which is given as an intravenous infusion.

the dose amount, infusion schedule, and duration will follow the study protocol and may be modified according to tolerability.

throughout the treatment period, you will attend scheduled visits where the study team will check for side effects and laboratory changes.

the primary focus is to identify dose limiting toxicities, which are side effects severe enough to prevent increasing the dose.

based on the safety information collected, the study will determine the recommended dose levels for both surzetoclax and etentamig when used together.

your dose may be increased, decreased, or kept the same depending on how well you tolerate the medication.

periodically, the study will evaluate how the disease responds to the therapy using measures such as overall response rate, progression‑free survival, and duration of response.

these assessments help determine whether the combination is effective.

treatment will conclude according to the study schedule or if the disease progresses or unacceptable side effects occur.

a final set of assessments will be performed to document safety outcomes and any changes in disease activity.